No Data
Qual Holdings --- Monthly Report (Consolidated) Achievements for November 2024.
QOL Holdings <3034> announced its monthly report (consolidated) for November 2024 on the 13th. The number of prescription requests for the month of November was 104.9% compared to the same month last year, and the dispensing fees were 104.0%. In November, both prescription requests and dispensing fees increased due to contributions from M&A and new store openings. The status of the group's stores is as follows. Regarding new openings, in November, QOL Anywhere Pharmacy (Saitama Prefecture) opened, and in December, QOL Pharmacy Nitori Mo was planned.
List of converted stocks (Part 2) [List of converted stocks for Parabolic Signal]
○ List of stocks for buy conversion market Code Stock Name Closing Price SAR Tokyo Stock Exchange main board <6879> Imagica G 527 469 <6954> fanuc corp 40063649 <6988> Nitto Denko 24402362 <6999> KOA 996957 <7226> Kyokuto Kaihatsu 23302231 <7240> NOK 23252206 <7250> Pacific Industry 13421285 <7261> mazda motor crp 982
Qual HD --- Launching 7 types of authorized generic pharmaceuticals consisting of 3 components.
On the 5th, Quaal Holdings <3034> announced that its subsidiary Daiichi Sankyo Esfa will launch three ingredients and seven products of authorized generic (AG) pharmaceuticals on the 6th, as announced in the official gazette. Daiichi Sankyo Esfa provides high-value-added generic pharmaceuticals featuring innovations in formulation, labeling, and packaging, as well as AGs that are identical to new drugs (branded pharmaceuticals) in terms of active ingredients, additives, and manufacturing methods. The products being launched include rivaroxaban tablets, a selective direct factor Xa inhibitor.
Qual Holdings - New release of 7 items of authorized generic pharmaceuticals with 3 components.
On the 5th, Qol Holdings <3034> announced that its subsidiary Daiichi Sankyo Esfa will launch three authorized generic (AG) pharmaceutical products comprising seven items as published in the official gazette on the 6th. Daiichi Sankyo Esfa provides high-value-added generic pharmaceuticals with innovations in formulations, labeling, and packaging, as well as AGs that are identical to new drugs (originator pharmaceuticals) in terms of active ingredients, additives, manufacturing methods, etc. The new products being launched include Rivaroxaban tablets, a selective direct factor Xa inhibitor.
List of Cloud Breakout Stocks [Ichimoku Balance Table, List of Cloud Breakout Stocks]
○ List of stocks breaking through the clouds in the market Code Stock Name Closing Price Leading Span A Leading Span B Tokyo main board <1433> Bestera 948 947 871.5 <1820> Nishimatsu Construction 5150 5123468.5 <1860> Toda Corporation 1003959.7 5994.5 <1871> PS 10491034.7 5956 <1884> Nihon Doro 1696 1684.7 51597.5
Qol Holdings: Confirmation letter
No Data